Mayo Foundation for Medical Education and Research

Other

Thomas C Spelsberg

Steven A Harris

Malayannan Subramaniam

Nalini M Rajamannan

Patrick C Roche

Merry Jo Velasquez

Materials and methods related to a transgenic non-human animal (e.g., a transgenic non-human mammal) whose genome comprises a disrupted TIEG allele are provided. Methods for making such transgenic non-human animals, and using them to identify and characterize agents that affect conditions related to TIEG activity, such as cardiac hypertrophy and bone formation also are provided. In addition, materials and methods related to the treatment of hypertrophic cardiomyopathy are provided.

Transgenic TIEG non-human animals

Methods to determine TIEF-1 polypeptide, or genetic rearrangements in the TIEF-1 gene, in a sample are provided. Also provided are TIEF-1 specific antibodies and nucleic acid probes, and methods of employing those antibodies and probes to detect breast cancer in situ in a mammalian tissue sample.

TGF-&bgr; inducible early factor-1 (TIEF-1) and a method to detect breast cancer

An isolated and purified DNA molecule encoding TGF-.beta. inducible early factor-1 (TIEF-1) is provided. A method of isolating a growth factor- or differentiation factor-inducible gene is also provided.

DNA encoding TGF-.beta. inducible early factor-1 (TIEF-1), a gene

Immortalized normal human fetal osteoblastic cells that express a temperature sensitive mutant of simian virus 40 large T antigen are provided.

Immortalized human fetal osteoblastic cells

A method and a test kit for rapidly determining the presence of functional cellular steroid receptors by assaying a tissue sample for nuclear steroid or antisteroid binding is disclosed which comprises treating the tissue with collagenase, incubating the isolated cells with a labelled steroid or a labelled antisteroid capable of complexing said receptors and measuring the bound nuclear radioactivity and the DNA of the isolated cellular nuclei.

Method and kit to assay for steroid receptor functionality in cancerous

A method for rapidly determining the presence of functional cellular steroid receptors by assaying a tissue sample for nuclear steroid or antisteroid binding is disclosed which comprises treating the tissue with collagenase, incubating the isolated cells with a labelled steroid or a labelled antisteroid capable of complexing said receptors and measuring the bound nuclear radioactivity and the DNA of the isolated cellular nuclei.

Nuclear binding assay for steroid receptor functionality in cancerous

A method for rapidly determining the presence of functional cellular steroid receptors by assaying a tissue sample for nuclear steroid binding is disclosed which comprises treating the tissue with collagenase, incubating the isolated cells with a labelled steroid capable of complexing said receptors and measuring the bound radioactivity and the DNA of the isolated cellular nuclei.

A continuous flow tissue homogenizer is disclosed and includes a generally tubular container (12) with an inner surface (60) defining a tissue homogenization chamber (19). One end of the container has an inlet (46) for the introduction of non-homogenized tissue in solution and the other end of the container has an outlet (36) for the discharge of homogenate. A pestle member (38) is disposed within the homogenization chamber and mounted to a shaft (40) for rotatably driving the pestle member. The pestle member has an outer surface (62) that is spaced apart from the inner surface of the container to provide a tissue disruption zone (64) therebetween. The pestle member divides the homogenization chamber into first portion (54) and second portion (56). A plurality of grooves (68) are circumferentially spaced about the outer surface of the pestle member and open into the first chamber portion to channel the tissue solution into the tissue disruption zone of the apparatus.

Growing community of inventors

Rochester, MN, United States of America

Thomas C Spelsberg